<br>        Inclusion Criteria:<br><br>          -  Subjects with a diagnosis of atopic dermatitis who are otherwise healthy.<br><br>          -  Male or female between 18 and 65 years of age inclusive.<br><br>          -  A female subject is eligible to participate if she is of:<br><br>             • Non-childbearing potential defined as pre-menopausal females with a documented tubal<br>             ligation or hysterectomy; or postmenopausal. Females on hormone replacement therapy<br>             (HRT) and whose menopausal status is in doubt will be required to use one of the<br>             protocol contraception methods if they wish to continue their HRT during the study.<br><br>          -  Male subjects with female partners of child-bearing potential must agree to use one of<br>             the protocol contraception methods.<br><br>          -  BMI within the range 19.0 - 29.0 kg/m2 (inclusive).<br><br>          -  Subjects must have body surface area (BSA) disease involvement of >5% as assessed by<br>             the rule of nines method.<br><br>          -  Patients must be willing to refrain from current active therapy for at least 10 days<br>             prior to dosing,<br><br>          -  Capable of giving written informed consent.<br><br>          -  Single QTc, QTcB < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.<br><br>          -  AST and ALT < 2xULN; alkaline phosphatase and bilirubin = 1.5xULN (isolated bilirubin<br>             >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).<br><br>        Exclusion Criteria:<br><br>          -  The subject presents with any systemic disorder, active skin disease or subjects who<br>             present with scars, moles, tattoos, body piercings, sunburn in the test area which<br>             could interfere with the assessment of lesions at screening.<br><br>          -  The subject has atopic dermatitis restricted to the face, the feet or the hands only.<br><br>          -  The subject has a current complication of atopic dermatitis for which treatment with<br>             anti-infectives are indicated.<br><br>          -  History of recent (< 6 months) active or presence of current superficial skin<br>             infections of viral aetiology<br><br>          -  The subject has been diagnosed as having contact dermatitis in area of target lesions,<br>             seborrheic dermatitis and/or occupational eczema at predilection sites of atopic<br>             dermatitis.<br><br>          -  The subject has had topical or transdermal treatments on or near the intended site of<br>             application within 14 days prior to first application of study medication.<br><br>          -  The subject has had systemic treatment for atopic dermatitis within 28 days of the<br>             first dose of study medication.<br><br>          -  Foreseeable intensive UV exposure during the study. Subjects must not be exposed to<br>             direct sunlight or skin tanning devices for the duration of the study.<br><br>          -  The subject has used topical treatment with tar or any corticosteroid within 14 days<br>             of the first dose of study medication except topical 1% hydrocortisone which may be<br>             used twice daily in patients with severe disease who require step-down therapy during<br>             the wash-out period until 3 days prior to study start, after which the hydrocortisone<br>             must be discontinued.<br><br>          -  The subject has used topical treatment with buproprion within 14 days of the first<br>             dose of study medication.<br><br>          -  History of cutaneous photodisorder.<br><br>          -  History of allergy to steroids or components of test medications.<br><br>          -  History or presence of skin (other than atopic dermatitis), hepatic or renal disease<br>             or any other condition known to interfere with absorption, distribution, metabolism or<br>             excretion of drugs.<br><br>          -  Subjects with a history of diaphoresis/excessive sweating not restricted to palms or<br>             face.<br><br>          -  A positive test for Hepatitis B or Hepatitis C antibody.<br><br>          -  Current or chronic history of liver disease, or known hepatic or biliary<br>             abnormalities.<br><br>          -  A positive pre-study drug/alcohol screen.<br><br>          -  A positive test for HIV antibody.<br><br>          -  History of regular alcohol consumption within 6 months of the study.<br><br>          -  The subject has participated in a clinical trial and has received an investigational<br>             product within the following time period prior to the first dosing day in the current<br>             study: 30 days, 5 half-lives or twice the duration of the biological effect of the<br>             investigational product (whichever is longer).<br><br>          -  Exposure to more than four new chemical entities within 12 months prior to the first<br>             dosing day.<br><br>          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary<br>             supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5<br>             half-lives (whichever is longer) prior to the first dose of study medication, unless<br>             in the opinion of the Investigator and GSK Medical Monitor the medication will not<br>             interfere with the study procedures or compromise subject safety.<br><br>          -  Where participation in the study would result in donation of blood or blood products<br>             in excess of 500 mL within a 56 day period.<br><br>          -  Unwillingness or inability to follow the procedures outlined in the protocol.<br><br>          -  Subject is mentally or legally incapacitated.<br><br>          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.<br><br>          -  Consumption of red wine, Seville oranges, grapefruit or grapefruit juice and/or<br>             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior<br>             to the first dose of study medication.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Subjects with a diagnosis of atopic dermatitis who are otherwise healthy.<br><br>          -  Male or female between 18 and 65 years of age inclusive.<br><br>          -  A female subject is eligible to participate if she is of:<br><br>             • Non-childbearing potential defined as pre-menopausal females with a documented tubal<br>             ligation or hysterectomy; or postmenopausal. Females on hormone replacement therapy<br>             (HRT) and whose menopausal status is in doubt will be required to use one of the<br>             protocol contraception methods if they wish to continue their HRT during the study.<br><br>          -  Male subjects with female partners of child-bearing potential must agree to use one of<br>             the protocol contraception methods.<br><br>          -  BMI within the range 19.0 - 29.0 kg/m2 (inclusive).<br><br>          -  Subjects must have body surface area (BSA) disease involvement of >5% as assessed by<br>             the rule of nines method.<br><br>          -  Patients must be willing to refrain from current active therapy for at least 10 days<br>             prior to dosing,<br><br>          -  Capable of giving written informed consent.<br><br>          -  Single QTc, QTcB < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.<br><br>          -  AST and ALT < 2xULN; alkaline phosphatase and bilirubin = 1.5xULN (isolated bilirubin<br>             >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).<br><br>        Exclusion Criteria:<br><br>          -  The subject presents with any systemic disorder, active skin disease or subjects who<br>             present with scars, moles, tattoos, body piercings, sunburn in the test area which<br>             could interfere with the assessment of lesions at screening.<br><br>          -  The subject has atopic dermatitis restricted to the face, the feet or the hands only.<br><br>          -  The subject has a current complication of atopic dermatitis for which treatment with<br>             anti-infectives are indicated.<br><br>          -  History of recent (< 6 months) active or presence of current superficial skin<br>             infections of viral aetiology<br><br>          -  The subject has been diagnosed as having contact dermatitis in area of target lesions,<br>             seborrheic dermatitis and/or occupational eczema at predilection sites of atopic<br>             dermatitis.<br><br>          -  The subject has had topical or transdermal treatments on or near the intended site of<br>             application within 14 days prior to first application of study medication.<br><br>          -  The subject has had systemic treatment for atopic dermatitis within 28 days of the<br>             first dose of study medication.<br><br>          -  Foreseeable intensive UV exposure during the study. Subjects must not be exposed to<br>             direct sunlight or skin tanning devices for the duration of the study.<br><br>          -  The subject has used topical treatment with tar or any corticosteroid within 14 days<br>             of the first dose of study medication except topical 1% hydrocortisone which may be<br>             used twice daily in patients with severe disease who require step-down therapy during<br>             the wash-out period until 3 days prior to study start, after which the hydrocortisone<br>             must be discontinued.<br><br>          -  The subject has used topical treatment with buproprion within 14 days of the first<br>             dose of study medication.<br><br>          -  History of cutaneous photodisorder.<br><br>          -  History of allergy to steroids or components of test medications.<br><br>          -  History or presence of skin (other than atopic dermatitis), hepatic or renal disease<br>             or any other condition known to interfere with absorption, distribution, metabolism or<br>             excretion of drugs.<br><br>          -  Subjects with a history of diaphoresis/excessive sweating not restricted to palms or<br>             face.<br><br>          -  A positive test for Hepatitis B or Hepatitis C antibody.<br><br>          -  Current or chronic history of liver disease, or known hepatic or biliary<br>             abnormalities.<br><br>          -  A positive pre-study drug/alcohol screen.<br><br>          -  A positive test for HIV antibody.<br><br>          -  History of regular alcohol consumption within 6 months of the study.<br><br>          -  The subject has participated in a clinical trial and has received an investigational<br>             product within the following time period prior to the first dosing day in the current<br>             study: 30 days, 5 half-lives or twice the duration of the biological effect of the<br>             investigational product (whichever is longer).<br><br>          -  Exposure to more than four new chemical entities within 12 months prior to the first<br>             dosing day.<br><br>          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary<br>             supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5<br>             half-lives (whichever is longer) prior to the first dose of study medication, unless<br>             in the opinion of the Investigator and GSK Medical Monitor the medication will not<br>             interfere with the study procedures or compromise subject safety.<br><br>          -  Where participation in the study would result in donation of blood or blood products<br>             in excess of 500 mL within a 56 day period.<br><br>          -  Unwillingness or inability to follow the procedures outlined in the protocol.<br><br>          -  Subject is mentally or legally incapacitated.<br><br>          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.<br><br>          -  Consumption of red wine, Seville oranges, grapefruit or grapefruit juice and/or<br>             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior<br>             to the first dose of study medication.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Subjects with a diagnosis of atopic dermatitis who are otherwise healthy.<br><br>          -  Male or female between 18 and 65 years of age inclusive.<br><br>          -  A female subject is eligible to participate if she is of:<br><br>             • Non-childbearing potential defined as pre-menopausal females with a documented tubal<br>             ligation or hysterectomy; or postmenopausal. Females on hormone replacement therapy<br>             (HRT) and whose menopausal status is in doubt will be required to use one of the<br>             protocol contraception methods if they wish to continue their HRT during the study.<br><br>          -  Male subjects with female partners of child-bearing potential must agree to use one of<br>             the protocol contraception methods.<br><br>          -  BMI within the range 19.0 - 29.0 kg/m2 (inclusive).<br><br>          -  Subjects must have body surface area (BSA) disease involvement of >5% as assessed by<br>             the rule of nines method.<br><br>          -  Patients must be willing to refrain from current active therapy for at least 10 days<br>             prior to dosing,<br><br>          -  Capable of giving written informed consent.<br><br>          -  Single QTc, QTcB < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.<br><br>          -  AST and ALT < 2xULN; alkaline phosphatase and bilirubin = 1.5xULN (isolated bilirubin<br>             >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).<br><br>        Exclusion Criteria:<br><br>          -  The subject presents with any systemic disorder, active skin disease or subjects who<br>             present with scars, moles, tattoos, body piercings, sunburn in the test area which<br>             could interfere with the assessment of lesions at screening.<br><br>          -  The subject has atopic dermatitis restricted to the face, the feet or the hands only.<br><br>          -  The subject has a current complication of atopic dermatitis for which treatment with<br>             anti-infectives are indicated.<br><br>          -  History of recent (< 6 months) active or presence of current superficial skin<br>             infections of viral aetiology<br><br>          -  The subject has been diagnosed as having contact dermatitis in area of target lesions,<br>             seborrheic dermatitis and/or occupational eczema at predilection sites of atopic<br>             dermatitis.<br><br>          -  The subject has had topical or transdermal treatments on or near the intended site of<br>             application within 14 days prior to first application of study medication.<br><br>          -  The subject has had systemic treatment for atopic dermatitis within 28 days of the<br>             first dose of study medication.<br><br>          -  Foreseeable intensive UV exposure during the study. Subjects must not be exposed to<br>             direct sunlight or skin tanning devices for the duration of the study.<br><br>          -  The subject has used topical treatment with tar or any corticosteroid within 14 days<br>             of the first dose of study medication except topical 1% hydrocortisone which may be<br>             used twice daily in patients with severe disease who require step-down therapy during<br>             the wash-out period until 3 days prior to study start, after which the hydrocortisone<br>             must be discontinued.<br><br>          -  The subject has used topical treatment with buproprion within 14 days of the first<br>             dose of study medication.<br><br>          -  History of cutaneous photodisorder.<br><br>          -  History of allergy to steroids or components of test medications.<br><br>          -  History or presence of skin (other than atopic dermatitis), hepatic or renal disease<br>             or any other condition known to interfere with absorption, distribution, metabolism or<br>             excretion of drugs.<br><br>          -  Subjects with a history of diaphoresis/excessive sweating not restricted to palms or<br>             face.<br><br>          -  A positive test for Hepatitis B or Hepatitis C antibody.<br><br>          -  Current or chronic history of liver disease, or known hepatic or biliary<br>             abnormalities.<br><br>          -  A positive pre-study drug/alcohol screen.<br><br>          -  A positive test for HIV antibody.<br><br>          -  History of regular alcohol consumption within 6 months of the study.<br><br>          -  The subject has participated in a clinical trial and has received an investigational<br>             product within the following time period prior to the first dosing day in the current<br>             study: 30 days, 5 half-lives or twice the duration of the biological effect of the<br>             investigational product (whichever is longer).<br><br>          -  Exposure to more than four new chemical entities within 12 months prior to the first<br>             dosing day.<br><br>          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary<br>             supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5<br>             half-lives (whichever is longer) prior to the first dose of study medication, unless<br>             in the opinion of the Investigator and GSK Medical Monitor the medication will not<br>             interfere with the study procedures or compromise subject safety.<br><br>          -  Where participation in the study would result in donation of blood or blood products<br>             in excess of 500 mL within a 56 day period.<br><br>          -  Unwillingness or inability to follow the procedures outlined in the protocol.<br><br>          -  Subject is mentally or legally incapacitated.<br><br>          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.<br><br>          -  Consumption of red wine, Seville oranges, grapefruit or grapefruit juice and/or<br>             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior<br>             to the first dose of study medication.<br>      ;<br>        Inclusion Criteria:<br><br>          -  Subjects with a diagnosis of atopic dermatitis who are otherwise healthy.<br><br>          -  Male or female between 18 and 65 years of age inclusive.<br><br>          -  A female subject is eligible to participate if she is of:<br><br>             • Non-childbearing potential defined as pre-menopausal females with a documented tubal<br>             ligation or hysterectomy; or postmenopausal. Females on hormone replacement therapy<br>             (HRT) and whose menopausal status is in doubt will be required to use one of the<br>             protocol contraception methods if they wish to continue their HRT during the study.<br><br>          -  Male subjects with female partners of child-bearing potential must agree to use one of<br>             the protocol contraception methods.<br><br>          -  BMI within the range 19.0 - 29.0 kg/m2 (inclusive).<br><br>          -  Subjects must have body surface area (BSA) disease involvement of >5% as assessed by<br>             the rule of nines method.<br><br>          -  Patients must be willing to refrain from current active therapy for at least 10 days<br>             prior to dosing,<br><br>          -  Capable of giving written informed consent.<br><br>          -  Single QTc, QTcB < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block.<br><br>          -  AST and ALT < 2xULN; alkaline phosphatase and bilirubin = 1.5xULN (isolated bilirubin<br>             >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).<br><br>        Exclusion Criteria:<br><br>          -  The subject presents with any systemic disorder, active skin disease or subjects who<br>             present with scars, moles, tattoos, body piercings, sunburn in the test area which<br>             could interfere with the assessment of lesions at screening.<br><br>          -  The subject has atopic dermatitis restricted to the face, the feet or the hands only.<br><br>          -  The subject has a current complication of atopic dermatitis for which treatment with<br>             anti-infectives are indicated.<br><br>          -  History of recent (< 6 months) active or presence of current superficial skin<br>             infections of viral aetiology<br><br>          -  The subject has been diagnosed as having contact dermatitis in area of target lesions,<br>             seborrheic dermatitis and/or occupational eczema at predilection sites of atopic<br>             dermatitis.<br><br>          -  The subject has had topical or transdermal treatments on or near the intended site of<br>             application within 14 days prior to first application of study medication.<br><br>          -  The subject has had systemic treatment for atopic dermatitis within 28 days of the<br>             first dose of study medication.<br><br>          -  Foreseeable intensive UV exposure during the study. Subjects must not be exposed to<br>             direct sunlight or skin tanning devices for the duration of the study.<br><br>          -  The subject has used topical treatment with tar or any corticosteroid within 14 days<br>             of the first dose of study medication except topical 1% hydrocortisone which may be<br>             used twice daily in patients with severe disease who require step-down therapy during<br>             the wash-out period until 3 days prior to study start, after which the hydrocortisone<br>             must be discontinued.<br><br>          -  The subject has used topical treatment with buproprion within 14 days of the first<br>             dose of study medication.<br><br>          -  History of cutaneous photodisorder.<br><br>          -  History of allergy to steroids or components of test medications.<br><br>          -  History or presence of skin (other than atopic dermatitis), hepatic or renal disease<br>             or any other condition known to interfere with absorption, distribution, metabolism or<br>             excretion of drugs.<br><br>          -  Subjects with a history of diaphoresis/excessive sweating not restricted to palms or<br>             face.<br><br>          -  A positive test for Hepatitis B or Hepatitis C antibody.<br><br>          -  Current or chronic history of liver disease, or known hepatic or biliary<br>             abnormalities.<br><br>          -  A positive pre-study drug/alcohol screen.<br><br>          -  A positive test for HIV antibody.<br><br>          -  History of regular alcohol consumption within 6 months of the study.<br><br>          -  The subject has participated in a clinical trial and has received an investigational<br>             product within the following time period prior to the first dosing day in the current<br>             study: 30 days, 5 half-lives or twice the duration of the biological effect of the<br>             investigational product (whichever is longer).<br><br>          -  Exposure to more than four new chemical entities within 12 months prior to the first<br>             dosing day.<br><br>          -  Use of prescription or non-prescription drugs, including vitamins, herbal and dietary<br>             supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5<br>             half-lives (whichever is longer) prior to the first dose of study medication, unless<br>             in the opinion of the Investigator and GSK Medical Monitor the medication will not<br>             interfere with the study procedures or compromise subject safety.<br><br>          -  Where participation in the study would result in donation of blood or blood products<br>             in excess of 500 mL within a 56 day period.<br><br>          -  Unwillingness or inability to follow the procedures outlined in the protocol.<br><br>          -  Subject is mentally or legally incapacitated.<br><br>          -  History of sensitivity to heparin or heparin-induced thrombocytopenia.<br><br>          -  Consumption of red wine, Seville oranges, grapefruit or grapefruit juice and/or<br>             pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days prior<br>             to the first dose of study medication.<br>